Press Releases Year None20212020201920182017 September 7, 2021 SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PDF Version August 30, 2021 SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma PDF Version August 4, 2021 SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights PDF Version August 3, 2021 SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference PDF Version August 3, 2021 SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations PDF Version July 27, 2021 SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer PDF Version July 20, 2021 SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041 PDF Version June 28, 2021 Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma PDF Version June 16, 2021 SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma PDF Version June 15, 2021 SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Next page next › Last page last »
September 7, 2021 SpringWorks Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference PDF Version
August 30, 2021 SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma PDF Version
August 4, 2021 SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights PDF Version
August 3, 2021 SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference PDF Version
August 3, 2021 SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations PDF Version
July 27, 2021 SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer PDF Version
July 20, 2021 SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041 PDF Version
June 28, 2021 Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma PDF Version
June 16, 2021 SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma PDF Version
June 15, 2021 SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference PDF Version
